ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• Epidermal growth factor receptor 3 (ERBB3) is implicated in activating the PI3K pathway in EGFR-mutant lung adenocarcinomas.
• Its precise role in tumorigenesis and therapeutic response remains to be fully elucidated.

Purpose of the Study:

• To investigate the role of ERBB3 in the initiation, progression, and treatment response of EGFR-driven lung adenocarcinomas.
• To understand the compensatory signaling mechanisms following ERBB3 loss in EGFR-mutant lung cancer.

Main Methods:

• Utilized tetracycline- and tamoxifen-inducible transgenic mouse models for EGFR-mutant lung adenocarcinomas.
• Investigated tumor initiation, growth suppression, and signaling pathway activation (EGFR, PI3K-AKT, ERK) upon Erbb3 deletion.
• Analyzed EGFR-mutant human cell lines to assess ERBB3-independent PI3K activation and compensatory pathways.

Main Results:

• ERBB3 is dispensable for the initiation of EGFR-mutant lung tumorigenesis.
• Established EGFR-mutant lung tumors show suppressed growth upon acute Erbb3 deletion.
• Tumors lacking ERBB3 retain PI3K-AKT pathway activation and sensitivity to EGFR inhibitors, with evidence of compensatory signaling via GAB1/GAB2, AKT, and ERK.
• ERBB3-independent PI3K pathway activation by mutant EGFR occurs in human cell lines, mediated by GAB adaptor proteins.
• Increased ERBB2 or MET phosphorylation correlates with reduced sensitivity to Erbb3 loss in human cell lines.

Conclusions:

• ERBB3 is not required for initiating EGFR-driven lung cancer but is critical for sustained tumor growth.
• Signaling plasticity exists in EGFR-mutant lung cancer, with alternative pathways compensating for ERBB3 loss.
• Understanding these compensatory mechanisms, including ERBB2 and MET signaling, is vital for developing effective therapeutic strategies against EGFR-mutant lung adenocarcinomas.